Advances in genotyping technology have allowed rapid genome-wide screening of common variants in large populations launching a new era in the investigation of the genetic basis of complex diseases. So far GWAS have contributed little in the field of PD[@R2]--[@R4]; likely because previous studies lacked power to detect effects of the size expected in these diseases.

The present study was designed as a two-stage GWAS. Characteristics of the cohorts are shown in [Table 1](#T1){ref-type="table"}. For stage I, genotyping was performed using Infinium BeadChips (Illumina, Inc.). Following quality control 463,185 SNPs were analyzed in 1,713 PD cases and 3,978 controls. To assess the homogeneity of our cohort, pair-wise Identity by State distances (IBS) were calculated using HapMap data as a reference. These analyses revealed that our samples share common Caucasian ancestry ([supplementary figures 1 and 2](#SD2){ref-type="supplementary-material"}). We chose not to use genomic control as false positive association, possibly caused by population substructure (lambda=1.17), would be controlled for by our two-stage design. Power calculations showed our sample had 80% power to detect variants conferring an odds ratio (OR) of 1.3 with an allele frequency of 10% ([supplementary figure 3](#SD2){ref-type="supplementary-material"}).

Each SNP was tested for association using a Cochran-Armitage genotypic trend model. Four SNPs on chromosome 4q22 within the *SNCA* locus exceeded Bonferroni corrected genome-wide significance threshold in stage I (most significant *p*=5.69×10^−9^, rs2736990; [Figure 1](#F1){ref-type="fig"}, [Table 2](#T2){ref-type="table"}). Three SNPs at the *MAPT* locus on chromosome 17q21 also surpassed genome-wide significance in stage I (most significant p=5.05×10^−8^, rs199533). A logistic regression analysis adjusted for the two first components of the multidimensional scaling values following calculation of pair-wise IBS distance suggests that the significant results obtained are not biased by population substructure ([supplementary material](#SD1){ref-type="supplementary-material"}).

Replication comprised genotyping of 384 SNPs selected based on the *p*-value observed in stage I ([supplementary table 1](#SD1){ref-type="supplementary-material"}). Genotyping was performed in an independent cohort of 3,452 cases and 4,756 controls from the US, Germany and Britain. Taking into account the results obtained from pairwise Identity by State distances calculations and considering that genetic heterogeneity and allelic heterogeneity are not likely to produce type I and type II errors when pooling white North American and white North European populations, we decided to analyze all Stage II samples together. Following quality control filtering, 345 SNPs were analyzed in 3,361 cases and 4,573 controls. Twenty-one SNPs within the *SNCA* and *MAPT* loci surpassed Bonferroni threshold for significance (*p*\<0.000145; [Table 2](#T2){ref-type="table"}; [supplementary table 2](#SD1){ref-type="supplementary-material"}).

Three hundred and forty five stage II SNPs passed our quality control procedures ([Supplementary table 1](#SD1){ref-type="supplementary-material"}). Notably, we observed clusters of SNPs showing improved association signals when combining our stage I and stage II datasets ([supplementary figure 4](#SD2){ref-type="supplementary-material"}). Although some of these SNPs are at loci that contain biologically plausible candidate genes for PD, they do not reach genome-wide significance and thus we have resisted drawing conclusions from these data; however, of particular note is a cluster of 7 SNPs in chromosome 10q24.32, with *p*-values below 1×10^−3^ ([Supplementary figure 5](#SD2){ref-type="supplementary-material"}). These and other variants showing a consistent, moderate association across stages warrant independent replication.

To further delineate the signals on *SNCA* and *MAPT*, allelic association of significant SNPs was tested, conditioned on alleles of other significant SNPs at the same locus. No independent signals were identified, suggesting that a single detectible pathogenic variant exists at each locus ([supplementary table 3](#SD1){ref-type="supplementary-material"}); however without complete sequence data across these loci we cannot rule out independent effects. We did not find evidence for epistasis between *SNCA* and *MAPT* risk alleles ([supplementary material](#SD1){ref-type="supplementary-material"}).

Analysis of the linkage disequilibrium (LD) structure across the *SNCA* locus revealed two blocks of LD ([Figure 2A](#F2){ref-type="fig"}). The 3′ block contains three of the four significantly associated SNPs, suggesting that the causal variant is located in the 3′ region of the *SNCA* gene. This is strengthened by analysis of the haplotype frequencies at this locus ([supplementary figure 6](#SD2){ref-type="supplementary-material"}) and previous studies[@R5]. The REP1 microsatellite in SNCA was previously associated with PD[@R5] and its pathological effect has been suggested to be mediated by gene expression[@R6]. Analysis of REP1 genotype data in 1,774 samples from the US cohort revealed the risk allele of REP1 is in LD with the 3′ risk alleles identified here (r^2^=0.365 with rs3857059; [supplemental figure 7A](#SD2){ref-type="supplementary-material"}), thus the association identified at the REP1 locus and the SNPs identified here may be the result of residual LD between these loci. This is supported by logistic regression analysis conditioned on REP1 genotypes, showing that association at REP1 is not independent from the association identified here ([supplementary material](#SD1){ref-type="supplementary-material"}). We recently reported a significant association of *SNCA* SNPs with another synucleinopathy, multiple system atrophy (*p*=5.5×10^−12^, MSA)[@R7]; comparison of these data reveals disparate *SNCA* risk SNPs in MSA and PD, a finding that may shed light on the exact pathogenic substrate and molecular etiology of these disorders ([supplementary table 4](#SD1){ref-type="supplementary-material"}).

As expected, one large highly inter-correlated block of high LD was observed across the *MAPT* locus ([Figure 2B](#F2){ref-type="fig"}). Available genotype data of the H1/H2 haplotypes in this region showed that the risk alleles of the associated SNPs are in LD with the H1 haplotype (r^2^=0.761 with rs393152; [supplementary figure 7B](#SD2){ref-type="supplementary-material"}). It is unclear from the current data whether the *MAPT* risk haplotype identified here corresponds to the subhaplotype associated with corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP)[@R8]. Because of the LD structure we cannot rule out other genes at this locus as the pathogenically relevant genes; however, *MAPT* is biologically the most plausible candidate.

Following data exchange with colleagues performing a PD GWAS in Japan we chose to study two loci implicated in Asian PD on chromosomes 1q32 and 4p15. In our stage I data, the most significant *p*-values at these 12 SNPs were 1.3×10^−4^ and 6.5×10^−3^ (1q32 and 4p15.3 respectively). The signal at 1q32 was significant enough to carry through to stage II replication, but this SNP had been excluded because of the low minor allele frequency in controls (0.03). Genotyping of these 12 SNPs was performed in an available subset of our replication cohort comprising 2,816 cases and 3,401 controls. The signal on chromosome 1q32 was replicated in this cohort (rs823128, *p*=1.9×10^−4^; [Table 2](#T2){ref-type="table"}). While this failed to surpass Bonferroni correction, the *p*-value across stages was highly significant (rs823128, *p*=7.3×10^−8^) and it is worth noting that the significance improved for all SNPs at this locus when combining stage I and II results ([Figure 2C](#F2){ref-type="fig"}). For these reasons and because the association at this locus was consistently detected in the Asian cohort[@R1] we are confident this signal represents a true association and this has been designated *PARK16*. Although we failed to replicate the signal on chromosome 4p15, which included only one gene, *BST1*, the low minor allele frequency of the associated SNPs in Caucasian individuals may have affected our ability to observe association.

Mutations in *SNCA* and *MAPT* have been associated with autosomal dominant forms of parkinsonism[@R9],[@R10]. Given this, it is interesting that we observed association proximal to *LRRK2*, which also contains mutations causing autosomal dominant PD[@R11],[@R12]. In stage I 23 SNPs upstream of *LRRK2*, and 12 SNPs within *LRRK2* were associated with PD (lowest *p*=5.03×10^−6^ in rs2896905, located in *SLC2A13*, 0.27Mb from *LRRK2*). Of these, 3 SNPs surpassed our threshold for replication and were analyzed in stage II. Only one SNP, 0.17Mb upstream of *LRRK2,* remained associated with PD after stage II (rs1491923, *p*=0.01; [supplementary material; Figure 2D](#SD2){ref-type="supplementary-material"}). While this did not surpass our threshold for multiple testing, the combined stage I and II *p-*values revealed a compelling association (*p*=1.6×10^−5^). Interestingly, the other 2 replicated SNPs at this locus were also nominally associated with PD after combining stage I and stage II datasets (*p*-values of 9.5×10^−5^ and 7.8×10^−3^; rs11564612 and rs2896905 respectively). Data from the Asian cohort also revealed a significant association with PD at this locus[@R1]. *SLC2A13*, neighboring *LRRK2*, cannot be ruled out as the gene of effect at this locus, however, *LRRK2* is clearly a more plausible candidate.

Although mutations and copy number variants of *SNCA* are the cause of rare familial forms of PD[@R10],[@R13], association of common variants has been more controversial. This study provides unequivocal evidence that variation in *SNCA* contributes to the etiology of sporadic PD. The clustering of associated SNPs in the 3′ UTR suggests that the causal variant might affect post-transcriptional RNA processing or RNA stability, possibly mediated by miRNA binding sites or by alternative splicing.

Association of the H1 haplotype at the *MAPT* locus with PSP and CBD has been described and replicated[@R8]; however, association studies of variants at *MAPT* in PD have produced conflicting results[@R14],[@R15]. Our data provide unequivocal evidence for an association of the *MAPT* locus with PD. This is surprising given the classic separation of synucleinopathies and tauopathies, although a cross-talk between molecular pathways characterized by different aggregating proteins has been repeatedly suggested. While there are additional genes at the *MAPT* locus, the role of *MAPT* in neurodegenerative diseases is well established and this association is biologically plausible.

We provide evidence for an association of PD with variability proximal to *LRRK2* and at a novel locus at 1q32 (*PARK16*). The kinase activity of lrrk2 is an attractive therapeutic target; our data suggests that this protein is also relevant to the etiology in sporadic PD patients without mutations. The *PARK16* locus spans 5 transcripts, *SNORA72*, *NUCKS1*, *RAB7L1*, *SLC41A1* and *PM20D1*. It will be important to define the immediate biological consequences of all four risk loci identified here. It is notable that three of the most significant loci identified here contain genes known to be mutated in Mendelian forms of parkinsonism. This supports the notion that rare familial disease is etiologically related to typical sporadic PD, and suggests that genes that contain common risk variants are excellent candidates to contain rare disease causing mutations. One might also predict that deep sequencing of these loci will reveal rare mutations that alter risk for, rather than cause, disease. It is also interesting that two of the four loci discussed here, are risk factors for other neurodegenerative diseases, including MSA (*SNCA*), PSP (*MAPT*) and CBD (*MAPT*).

The combined population attributable risk associated with the identified loci, considering the genotypic counts of those most associated SNPs in our cohort, is approximately 25% ([supplemental methods](#SD1){ref-type="supplementary-material"}). Our study was a retrospective case-control study and the frequency of the risk variants detected might not reflect the frequencies of true causal variants; thus these values should be interpreted with caution.

In an attempt to define a biological consequence of risk variants, we mined data produced within our laboratory. In this work genome wide genotyping and expression profiling of \>22,000 transcripts was performed in 133 human frontal cortex samples, allowing us to determine SNPs significantly associated with expression level. These data revealed a strong association between genotype at the risk alleles of the *MAPT* locus and expression levels of both *MAPT* and *LRRC37A* ([figure 3](#F3){ref-type="fig"}), in addition to less significant association with expression levels of other transcripts at this locus, but did not reveal association between risk SNPs and expression levels of proximal genes at the *SNCA*, *LRRK2* or *PARK16* loci ([Supplementary table 5](#SD1){ref-type="supplementary-material"}, [figure 8](#SD2){ref-type="supplementary-material"}). Notably the alleles at the *MAPT* locus associated with increase risk of PD are associated with increased expression of *MAPT* in the human brain.

We show for the first time a clear role for common genetic variability in the risk of developing PD. Further we describe a possible population specific genetic heterogeneity in this disorder, since the association to MAPT was absent in the Asian cohort. This observation has potential implications for the analysis of complex traits across populations; such genetic heterogeneity, particularly at minor risk loci, has the potential to mask true associations when analyses are performed across populations. With the discovery of the *PARK16* locus in the Asian population, this highlights the power of comparing GWAS across different populations. A further increase in the number and size of cohorts for GWAS in PD will likely reveal additional common genetic risk loci and these, in turn, will improve understanding and ultimately treatment of this devastating disorder.
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[Methods]{.ul} and associated references appear online. *Note:* [Supplementary information](#SD1){ref-type="supplementary-material"} *is available on the Nature Genetics website*.

Supplementary Material {#S2}
======================

We thank the subjects involved in this study whose contribution made this work possible. This work used samples and clinical data from the NINDS Human Genetics Resource Center DNA and Cell Line Repository (<http://ccr.coriell.org/ninds>). This work was supported in part by the Intramural Research Programs of the National Institute on Aging, the National Institute of Neurological Disorders and Stroke, the National Institute of Environmental Health Sciences, the National Cancer Institute, National Institutes of Health, Department of Health and Human Services; project numbers Z01 AG000949-02 and Z01-ES101986. The KORA research platform (KORA: Cooperative Research in the Region of Augsburg; [www.gsf.de/KORA](www.gsf.de/KORA)) was initiated and financed by the GSF---National Research Centre for Environment and Health, which is funded by the German Federal Ministry of Education, Science, Research and Technology and by the State of Bavaria.

The study was additionally funded by the German National Genome Network (NGFNplus \#01GS08134; German Ministry for Education and Research) and in addition by the German BMBF NGFN (01GR0468). This work also was supported by NIH NINDS P30NS05710 (Neuroscience Blueprint Grant) and Clinical Sciences Translational Award RR024992 to Washington University in St. Louis and the Greater St. Louis Chapter of the American Parkinson Disease Association. Authors received support from the Medical Research Council, UK.

Written informed consent was obtained for all participating subjects. Samples derived from the Laboratory of Neurogenetics, NIA, NIH, USA were approved by the Institutional Review Board of the National Institute on Aging; 2003-081 and 2008-146. The specific approval committes for the German samples were as follows: KORA: Bayerische Arztekammer; Popgen/Kiel: Ethik-Kommission der Medizinischen Fakultat der Christian-Albrechts-Universitat zu Kiel; Tubingen: Ethik-Kommission der Medizinischen Fakultat und am Universitatsklinikum Tubingen; Lubeck: Ethikkommission der Medizinischen Fakultat der Universitat zu Bochum: Ethik-Kommission der Medizinischen Fakultat der Ruhr-Universitat Bochum; Munchen: Ethikkommission der Med. Fakultat der LMU Munchen. Samples collected in the United Kingdom received approval from the Joint Research Ethics Committee of the National Hospital and Institute of Neurology. Samples collected from the Parkinson's, Genes & Environment (PAGE) study received approval by the Institutional review Board of NIEHS: 06-E-N093.

All authors participated in critical revision of the manuscript for intellectual content.

**AUTHOR CONTRIBUTIONS**

J.S.S. performed genotyping, conducted the statistical analyses and participated in writing the manuscript, C.S. conducted the statistical analyses and participated in writing the manuscript, J.M.B. performed genotyping, conducted the statistical analyses and participated in writing the manuscript, M.S. conducted the statistical analyses and participated in writing the manuscript, J.R.G. conducted the statistical analyses, D.B. contributed samples and collected phenotypic data, C.P.-R. contributed samples, performed genotyping, P.L. performed genotyping, S.W.S. performed genotyping, D.G.H. performed genotyping, R.K. contributed samples and collected phenotypic data, M.F. performed genotyping, C.K. contributed samples and collected phenotypic data, A.G. contributed samples, J.P. contributed samples and collected phenotypic data, M.B. performed genotyping, M.A.N. conducted the statistical analyses, T.I. contributed samples and collected phenotypic data, C.G. contributed samples and collected phenotypic data, H.H. contributed samples and collected phenotypic data, M.S. conducted the statistical analyses, M.S.O. contributed samples and collected phenotypic data, M.C. performed eQTL analysis, K.D.F. contributed samples, H.H.F. contributed samples, B.J.T. performed eQTL analysis, S.S. contributed samples and collected phenotypic data, S.A. performed genotyping, R.Z. performed genotyping, K.G. contributed samples and collected phenotypic data, M. van der B. performed eQTL analysis, G.L. contributed samples, S.J.C contributed control samples, A.S. contributed samples, Y.P. contributed samples, A.H. contributed samples, J.G. contributed samples, X.H. contributed samples, N.W.W. contributed samples and collected phenotypic data, D.L. contributed samples and collected phenotypic data, G.D. contributed samples and collected phenotypic data, H.C. contributed samples and collected phenotypic data, O.R. obtained funding and supervised genotyping, J.A.H. contributed samples and collected phenotypic data, A.B.S. designed and supervised the study, contributed samples and collected phenotypic data and participated in writing the manuscript, T.G. designed and supervised the study, contributed samples and collected phenotypic data and participated in writing the manuscript

![Graphical representation of p values in stage I and stage II. A) In stage I, p values are log transformed (y-axis) and plotted against chromosomes (x-axis). The red line indicates the Bonferroni threshold. Signals indicated in red are on chromosome 4 and chromosome 17 and surpass Bonferroni threshold for genome wide significance. B) log transformed p-values of Stage II SNPs (y-axis) are plotted against chromosomes (x-axis). Signals indicated in red are on chromosome 4 and chromosome 17 and surpass Bonferroni threshold for multiple testing](nihms154602f1){#F1}

![Association and recombination rates across *SNCA*, *MAPT*, *PARK16* and *LRRK2*. −log~10~ p values are shown for stage I and II analyses, annotated transcripts are shown across the top of each plot. Red dotted line indicates threshold for genome wide significance in stage I and orange line indicates threshold for significance of stage II.](nihms154602f2){#F2}

![Expression quantitative trait loci across the *MAPT* locus measured in 133 human frontal cortex samples; panel A shows association between genotypes and transcript levels across the *MAPT* locus. In this analysis the allelic load at genotyped polymorphisms across the locus is tested for association with transcript levels of each gene across the locus. The results of the analysis are shown as log transformed *p* values color-coded to match the transcript of interest. Notably genotypes across this locus are associated with *MAPT* (pink) and *LRRC37A* (blue) levels. Boxplots in panels B and C illustrate a dose relationship between allele load at the most significantly associated PD SNP (rs393152) and expression of *MAPT* (B) and *LRRC37A* (C), *p* values 4.1×10^−6^ and 1.7×10^−13^ respectively. Notably, the allele associated with higher risk for PD, A, is associated with high levels of *MAPT* expression and low levels of *LRRC37A* expression.](nihms154602f3){#F3}

###### 

Study characteristics of cases and controls in stage I and II

                    cases        controls                                      
  ---------- ------ ------------ ------------- ------ ------------ ----------- ------
  Stage I    USA    988          55.9 (15.1)   1.09   3071         62 (15.6)   0.96
  Germany    757    56 (11.64)   1.49          976    NA           1.08        
                                                                               
  Stage II   USA    1528         62.5 (8.55)   2.44   2044         63 (15.6)   2.45
  Germany    1100   61 (11.32)   1.37          2168   57 (10.54)   1.4         
  UK         824    59 (12.3)    3.5           544    NA           0.57        

aao = age at onset; aae = age at examination; s.d. = standard deviation; NA = not available

###### 

The top three SNPs of the 2 loci that surpass Bonferroni threshold for multiple testing in both stages and the top three SNPs in the LRRK2 locus and the additional loci in chromosomes 1 and 4.

  locus                                                 Stage I   Stage II   Stage I + II combined                                                                   
  ------------------------------ ---- ----------- ----- --------- ---------- ----------------------- ------ ------ ------ ---------- ------ ------ ------ ---------- ------
  Genome-wide significant loci                                                                                                                                       
  rs393152                       17   41074926    G/A   0.22      0.18       1.42E-07                0.76   0.22   0.18   1.69E-09   0.78   0.18   0.22   1.95E-16   0.77
  rs199533                       17   42184098    T/C   0.20      0.16       5.05E-08                0.75   0.20   0.17   7.95E-08   0.79   0.17   0.20   1.09E-14   0.78
  rs17563986                     17   41347100    C/T   0.22      0.18       3.44E-07                0.77   0.21   0.18   3.21E-08   0.79   0.18   0.22   1.67E-14   0.78
  rs2736990                      4    90897564    C/T   0.46      0.52       5.69E-09                1.27   0.46   0.51   5.52E-09   1.20   0.51   0.46   2.24E-16   1.23
  rs3857059                      4    90894261    G/A   0.07      0.10       3.60E-08                1.49   0.07   0.10   3.39E-08   1.43   0.10   0.07   3.74E-15   1.48
  rs11931074                     4    90858538    T/G   0.07      0.10       4.78E-08                1.49   0.08   0.10   3.75E-08   1.42   0.10   0.07   1.62E-14   1.46
                                                                                                                                                                     
  Other loci                                                                                                                                                         
  rs823128                       1    203980001   C/T   0.04      0.03       1.90E-04                0.64   0.04   0.03   1.96E-04   0.68   0.03   0.04   7.29E-08   0.66
  rs11240572                     1    204074636   T/G   0.04      0.02       1.30E-04                0.63   0.04   0.03   1.81E-03   0.72   0.03   0.04   6.11E-07   0.67
  rs823156                       1    204031263   C/T   0.18      0.16       4.31E-03                0.85   0.17   0.16   0.06       0.93   0.16   0.18   7.60E-04   0.89
  rs12646913                     4    15348374    G/A   0.08      0.07       0.041                   0.85   0.08   0.07   0.32       0.97   0.07   0.08   0.03       0.92
  rs4698412                      4    15346446    G/A   0.44      0.43       0.085                   0.93   0.45   0.43   0.14       0.95   0.43   0.44   0.03       0.94
  rs12502586                     4    15335662    A/G   0.10      0.12       6.50E-03                1.20   0.10   0.10   0.89       1.00   0.11   0.10   0.07       1.08
  rs11564162                     12   38729159    C/T   0.21      0.18       4.00E-05                0.78   0.21   0.19   0.10       0.93   0.19   0.21   9.52E-05   0.87
  rs2896905                      12   38779683    T/C   0.40      0.35       5.03E-06                0.82   0.38   0.38   0.73       1.01   0.37   0.39   7.81E-03   0.93
  rs1491923                      12   38877384    C/T   0.31      0.34       2.20E-04                1.20   0.31   0.33   0.01       1.10   0.33   0.31   1.55E-05   1.14

Position from NCBI genome build 36; Chr. = Chromosome; MAF U = minor allele frequency in controls; MAF A = minor allele frequency in cases; p-value = nominal p-value of trend test; cOR = common OR.
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